(NASDAQ: INDP) Indaptus Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.07%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.04%.
Indaptus Therapeutics's earnings in 2026 is -$15,423,500.On average, 3 Wall Street analysts forecast INDP's earnings for 2026 to be -$873,883,106, with the lowest INDP earnings forecast at -$839,613,180, and the highest INDP earnings forecast at -$899,585,550. On average, 3 Wall Street analysts forecast INDP's earnings for 2027 to be -$608,864,124, with the lowest INDP earnings forecast at -$584,987,099, and the highest INDP earnings forecast at -$626,771,892.
In 2028, INDP is forecast to generate $107,366,665 in earnings, with the lowest earnings forecast at $103,156,207 and the highest earnings forecast at $110,524,508.